Table 2.
Demographics and clinical characteristics of COVID-19 patients (n=513) clustered according to their immune cell composition during SARS-CoV-2 infection.
| Characteristics | Unclustered patient (N = 1; 0.2%) | Immunotype 1 (N = 74; 14.4%) | Immunotype 2 (N = 268; 52.3%) | Immunotype 3 (N = 170; 33.1%) | Significance |
|---|---|---|---|---|---|
| Age (years) | |||||
| 18–30 | 0 (0%) | 1 (1%) | 2 (0.7%) | 16 (9%) | b,c |
| 31–55 | 1 (100%) | 24 (32%) | 76 (28%) | 88 (52%) | a,b |
| 56–70 | 0 (0%) | 22 (30%) | 104 (39%) | 32 (19%) | b,c |
| >70 | 0 (0%) | 27 (36%) | 86 (32%) | 34 (20%) | a,c |
| Female, no. (%) | 1 (100%) | 31 (42%) | 121 (45%) | 107 (63%) | b,c |
| Comorbidities, no. (%) | |||||
| Any | 1 (100%) | 49 (66%) | 145 (54%) | 61 (36%) | b,c |
| Diabetes | 0 (0%) | 13 (18%) | 33 (12%) | 12 (7%) | ns |
| Hypercholesterolemia | 0 (0%) | 7 (9%) | 30 (11%) | 15 (9%) | ns |
| Hypertension | 0 (0%) | 33 (45%) | 109 (41%) | 36 (21%) | b,c |
| Cardiovascular disease | 0 (0%) | 14 (19%) | 32 (12%) | 10 (6%) | b |
| Cancer | 1 (100%) | 7 (9%) | 11 (4%) | 6 (4%) | ns |
| Medical care, no. (%) | |||||
| Non-hospitalized | 0 (0%) | 4 (5%) | 41 (15%) | 73 (43%) | a,b,c |
| Hospitalized | 1 (100%) | 70 (95%) | 227 (85%) | 97 (57%) | a,b,c |
| ICU | 1 (100%) | 16 (22%) | 9 (3%) | 6 (4%) | a,b |
| Hospitalization, median, days | 26 | 10 | 7 | 8 | a,c |
| Outcome, no. (%) | |||||
| Died | 1 (100%) | 14 (19%) | 7 (3%) | 1 (0.6%) | a,b |
ICU, intensive care unit.
a, significant difference between immunotypes 1 and 2.
b, significant difference between immunotypes 1 and 3.
c, significant difference between immunotypes 2 and 3.
ns, no significant differences among immunotypes.